Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment

Kruse, Gregory; Wong, Bruce; Duh, Mei Sheng; Lefèbvre, Patrick; Lafeuille, Marie-Hélène; Fastenau, John

doi:10.1007/s40273-015-0285-8

Cited by 2 publications

(3 citation statements)

References 195 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also regarding other elements of care for psychosis or schizophrenia, a range of cost-effectiveness studies have been performed. Several of these used health economic decision models, using various modelling techniques [27]. Most modelbased economic evaluations focused on pharmacological interventions in stages later than 'ultra-high risk of psychosis' (UHR) or 'first episode psychosis' (FEP) [28][29][30][31][32][33][34][35][36][37].…”

Section: Introductionmentioning

confidence: 99%

Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis

Wijnen

Thielen

Konings

et al. 2019

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Background: This study aims to report on the design of a model to determine the cost-effectiveness of prevention and treatment of early psychosis (PsyMod) and to estimate ten-year cost-effectiveness and budget impact of interventions targeting individuals with ultra-high risk (UHR) of developing psychosis or with first episode psychosis (FEP). Methods: PsyMod was built in parallel with the development of a new standard of care for treatment of early psychosis in the Netherlands. PsyMod is a state-transition cohort simulation model and considers six health states, namely ultra-high risk of psychosis (UHR), FEP, post-FEP, no-UHR, recovery/remission, and death. Results are expressed as total healthcare costs, QALYs, incremental cost-effectiveness ratio (ICER), and budget impact. Results: PsyMod was used to extrapolate budget impact and cost-effectiveness of cognitive behavioural therapy for preventing FEP for individuals at UHR of psychosis (CBTuhr) compared to care as usual. CBTuhr resulted in a per-patient increase of 0.06 QALYs and a per patient cost reduction of €654 (dominant ICER) with a reduction in 5-year healthcare costs of €1,002,166. Conclusions: PsyMod can be used to examine cost-effectiveness and budget impact of interventions targeting prevention and treatment of FEP and is freely available for academic purposes upon request by the authors. ARTICLE HISTORY

show abstract

Section: Introductionmentioning

confidence: 99%

Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis

Wijnen

Thielen

Konings

et al. 2019

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

show abstract

“…This approach to the evaluation of atypical treatments for schizophrenia has been used since 1990 [4]. In the current literature, model-based economic evaluations outweigh clinical trial-based analyses [5,6]. However, model-based studies may generate inconsistent conclusions on cost-effectiveness for the same comparison, even when the same modelling technique is used [7].…”

Section: Introductionmentioning

confidence: 99%

“…Recent systematic reviews have not presented current models of pharmacotherapy for schizophrenia, as they have narrowed their search to long-acting/extended-release antipsychotics [5], newer second-generation agents [6], and the relationship between modelling technique and reported outcomes [7]. Although Nemeth et al [8].…”

Section: Introductionmentioning

confidence: 99%

Systematic review of pharmacoeconomic models for schizophrenia

Zhou

Millier

Toumi

2018

Journal of Market Access & Health Policy

View full text Add to dashboard Cite

Background: Economic models are broadly used in the economic evaluation of antipsychotics in schizophrenia. Our objective was to summarize the structure of these models.Methods: Model-based economic evaluations of antipsychotics in schizophrenia were identified through Medline and Embase. General information was extracted including analysis type, model type, perspective, population, comparator, outcome, and timeframe. Model-specific structures for decision tree (DT), cohort- and patient-level Markov model (CLMM, PLMM), and discrete-event simulation (DES) models were extracted.Results: A screen of 1870 records identified 79 studies. These were mostly cost-utility analyses (n = 48) with CLMM (n = 32) or DT models (n = 29). They mostly applied payer perspective (n = 68), focused on general schizophrenia for relapse prevention (n = 73), compared pharmacotherapies as first-line (n = 71), and evaluated incremental cost per quality-adjusted life year (QALY) gained (n = 40) with a 1-year (n = 32) or 5-year (n = 26) projection. DT models progressed with the branching points of response, relapse, discontinuation, and adherence. CLMM models transitioned between disease states, whereas PLMM models transitioned between adverse event states with/without disease state. DES models moved forward with times to remission, relapse, psychiatrist visit, and death.Conclusions: A pattern of pharmacoeconomic models for schizophrenia was identified. More subtle structures and patient-level models are suggested for a future modelling exercise.

show abstract

Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment

Cited by 2 publications

References 195 publications

Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis

Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis

Systematic review of pharmacoeconomic models for schizophrenia

Contact Info

Product

Resources

About